Clinical Trial Update: Paclitaxel, Topotecan, and Estramustine in Treating Patients With Metastatic Hormone-Refractory Prostate Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating paclitaxel, topotecan, and estramustine for metastatic hormone-refractory prostate cancer has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Estramustine (estramustine)
• PACLITAXEL (PACLITAXEL)
• Topotecan (topotecan)

Snippet

Sponsor: Fox Chase Cancer Center | Conditions: Prostate Cancer | Phase 2 | Status: WITHDRAWN